Some synergies with the BTK family inhibitor ibrutinib (PCI32765, FDA approved for use against several hematological cancers which also inhibits BMX, a BTK family member expressed in carcinoma52 are also seen. The gene discussed is BTK; the disease is hematopoietic and lymphoid cell neoplasm.